Quantcast

Latest Herceptin Stories

2008-08-28 15:00:47

Harry Connick, Jr. will soon be seen in "Living Proof," a TV movie about an L.A. doctor's work developing the breast cancer drug Herceptin, Lifetime said. Connick Jr. is an Emmy Award-winning actor and Grammy Award-winning singer who has appeared in the films "Hope Floats" and "Memphis Belle," as well as in the TV series "Will & Grace" and the Broadway musical "The Pajama Game." The Lifetime Original Movie, "Living Proof," is based on the true story of Dr. Dennis Slamon and his efforts...

2008-08-28 12:01:02

LOS ANGELES, Aug. 28 /PRNewswire/ -- Emmy(R) and Grammy(R) Award winner Harry Connick, Jr. ("Will & Grace,""Hope Floats") stars in the Lifetime Original Movie, "Living Proof," the moving true story of Dr. Dennis Slamon, the UCLA doctor who helped develop the life saving breast cancer drug, Herceptin, and his efforts to keep the drug trials afloat and save the lives of thousands of women. (Logo: http://www.newscom.com/cgi-bin/prnh/20080804/NYM123LOGO) Academy Award(R)-winning actress...

2008-08-13 15:00:14

By HUNT, Tom; NZPA Nelson breast cancer sufferers have been dealt a double blow, with a decision not to increase funding for the drug Herceptin, and a discovery by the local health board that it was over- funding treatment. Government drug-buying agency Pharmac yesterday announced it would not increase funding for Herceptin - which is used to treat the aggressive Her2 positive form of breast cancer - from a nine- week course to a one-year course. In April, the High Court ordered...

2008-07-30 09:01:27

By 2012, sales of monoclonal antibodies will represent nearly 50% of oncology drug sales, according to a new study by Cutting Edge Information. Successful brands such as Rituxan, Herceptin and Erbitux are all expected to grow by anywhere from 23% to 80% by 2013. Furthermore, there are several monoclonal antibodies, such as Amgen's Denosumab and Bristol-Myers Squibb's ipilumumab, in development poised to experience similar growth after they launch. The new report, "The Oncology Market...

2008-07-30 09:00:23

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has initiated a Phase 2 clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer. In collaboration with Merck & Co. Inc., deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients with several different cancer types. Under terms of the...

2008-07-14 09:00:14

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

2008-07-08 09:01:11

Invitrogen Corporation, (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2 CISH Kit, indicated as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin(R)) treatment is being considered. The approval marks the first PMA that Invitrogen has received from the FDA. "The introduction of...

2008-07-08 09:00:12

The U.S. Food and Drug Administration said it's approved a genetic test for determining if breast cancer patients should be treated with the drug Herceptin. The SPOT-Light HER2 CISH kit is a test that measures the number of copies of the HER2 gene in tumor tissue. That gene regulates the growth of cancer cells. A healthy breast cell has two copies of the HER2 gene, which regulates how cells grow, divide and make repairs. The FDA said patients with breast cancer might have more copies of...

2008-07-08 06:00:36

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that, effective July 15, the HERmark(TM) Breast Cancer Assay will be available to physicians throughout the U.S. for assessment of HER2 status in patients with breast cancer. HERmark provides a precise and quantitative measurement of HER2 total protein and HER2 homodimer levels and will be offered as a CLIA-validated assay through Monogram's CAP-certified clinical laboratory....

2008-06-17 15:00:10

By MUSSEN, Deidre WHEN AUCKLAND cancer patient and mother of three Tui Allen needs her regular dose of Herceptin, she gets on a plane and flies to Palmerston North. The effort is saving her nearly $40,000 a year. That's the difference between the price an Auckland cancer specialist told her she'd have to pay for the drug, and the price on offer in Palmerston North. Allen was diagnosed last year, at only 40, with an aggressive breast cancer and was told she needed Herceptin. But her...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related